| Eastern Aroostook Rsu 39 | |
|
628 Main St Caribou ME 04736-4421 | |
| (207) 496-6311 | |
| (207) 498-3261 |
| Full Name | Eastern Aroostook Rsu 39 |
|---|---|
| Speciality | Clinic/center - Student Health |
| Location | 628 Main St, Caribou, Maine |
| Authorized Official Name and Position | Frank Mcelwain (SUPERINTENDENT OF SCHOOLS) |
| Authorized Official Contact | 2074966311 |
| Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
| Mailing Address | Practice Location Address |
|---|---|
| Eastern Aroostook Rsu 39 628 Main St Caribou ME 04736-4421 Ph: (207) 496-6311 | Eastern Aroostook Rsu 39 628 Main St Caribou ME 04736-4421 Ph: (207) 496-6311 |
| NPI Number | 1285934943 |
|---|---|
| Provider Enumeration Date | 10/28/2010 |
| Last Update Date | 10/28/2010 |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285934943 | NPI | - | NPPES |
| 434729100 | Other | ME | MAINECARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261QS1000X | Clinic/center - Student Health | 434729100 (Maine) | Primary |
News Archive
A parents advocacy group has called for a boycott of entertainment and sporting venues which promote and sell junk food.
Psychiatric disorders are prevalent among current and former inmates of correctional institutions, but what has been less clear is whether incarceration causes these disorders or, alternatively, whether inmates have these problems before they enter prison.
Prasco Laboratories announced today that they have signed a distribution and supply agreement with Stiefel Laboratories, Inc., a GlaxoSmithKline company, for Clobetasol Propionate Foam 0.05%, the latest product in Prasco's line of authorized generics. Under the terms of the agreement, Prasco will market and distribute Clobetasol Propionate Foam 0.05% in 50g and 100g canisters in the U.S. under the Prasco label.
Fitch Ratings assigns a 'BBB+' rating to the following City of Owensboro, Kentucky health system revenue bonds:
LEE011, a small-molecule inhibitor of cyclin-dependent kinases (CDK) 4/6 being developed by Novartis Oncology, showed promising results in drug-resistant melanoma and drug-resistant breast cancer when tested in combination with other targeted therapies, and based on these preclinical results, several phase I clinical trials were launched recently, according to results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held October 19-23.
› Verified 4 days ago